Camurus Ab

good day everyone and thank you for taking the time to join our first earnings call for 2024. so before starting the presentation please notice our forward local statements so the agenda for today's call includes first quarter highlights financial results we will then move to commercial and pipeline updates and finish off with a q a And with me on the call today, as previously, are John Garay, our chief financial officer, and Richard Jameson, our chief commercial officer. So starting out with our highlights in the quarter, cameras had a productive first quarter with strong profitability and pipeline progress. Total revenues grew by 37% year-on-year to 390 million SEC, which is the midpoint of our provided guidance. with profit before tax in the quarter of close to 100 million SEK. Our financial position was further strengthened by a successful directed share issue to support inorganic growth opportunities, accelerate U.S. commercial preparations for CAM 2029 in neuroendocrine tumors and polycystic liver disease, and enhance our manufacturing capabilities. From a commercial perspective, we continued strengthening our leading position in opioid dependence treatment across geographies. Buvidal sales increased by 29% year-on-year to 364 million SEC at reported rates. In the U.S., Brixadi showed strong and accelerating growth, resulting in an approximate threefold increase in sales and royalty in the first quarter versus Q4 2023. So on the R&D side, we received FDA acceptance for the review of MDA for Oclase in acromegaly with a PDUFA date in October this year. A corresponding application has now been submitted to the EMA. And outside the acromegaly area, we progressed the Sorento study of CAM-2029 in neuroendocrine tumors and completed patient recruitment in the Positano trial in polycystic liver disease. Importantly, we also advanced several early development programs, including completing preclinical assessments of a novel monthly formulation of semaglutide. Based on the data received, we are preparing for a first clinical study, planned to be started towards the end of this year. And with this short introduction, I will hand over to John for the finances.

Thanks a lot, Fredrik, and good afternoon, everyone. During this quarter, Camurus continued its development, delivering a strong profitability and remaining on track to meet 2024 market guidance and 2027 vision. I would like to share now key highlights of our financial performance this quarter. Camurus achieved 390 million SEG total revenue in the quarter, delivering a growth of 37% versus same period last year with product sales of 364 million SEC growing 29% versus prior year and basically aligned with prior quarter. Swedish Kronor appreciation has impacted negatively reported figures by 1% year-on-year basis and 3% versus prior quarter. Bricsaddy sales in the U.S. represented a 26 million SEC royalty income in the quarter following its commercial launch of September last year. Company profit before taxes was 97 million sec, achieving an earning per share after dilution of 1.32 Swedish kronor, equivalent to a profit after tax of 78 million sec in the quarter. Finally, our cash position progressed positively during the quarter, ending at 2.3 billion sec, including 1,026 million sec obtained via a directed share issue carried out in January in the size of 2 million shares. Moving to next slide, we can see the main components of our profit before taxes. Company gross margin reached 92.1% in the quarter, representing an improvement of 222 basic points versus same period prior year. The improvement was driven by three major factors. Supply chain efficiencies, driven by Boobidal volumes scale-up, represented 200 basic points. Secondly, 60 basic points are driven by Brixa deroyality. And thirdly, FX represented a negative impact of minus 45 basic points. Total OPEX reached 289 million SEC, representing a 57% increase versus same period prior year, driven by following factors. Marketing and distribution investment to support marketing penetration in owned territories, expansion of Boobidal into new markets, and U.S. operations grew 23% to 93 million SEC. Administrative expenses aligned with corporate evolution to substantiate company development grew 73% versus same period Asia to 16 million SEC. R&D investment reached 180 million SEC Growing 81% versus same period prior year, driven by recruitment completion, and progress in our preclinical and clinical pipeline. Company profit before taxes reached 97 million SEG, growing 26% versus prior year. Company cash position at quarter end was 2.3 billion SEG. Camorus improved its cash position by 1,084 million SEC in the quarter, driven by following factors. Firstly, company operations generated 139 million SEC. Secondly, working capital increased by 102 million SEC, driven mainly by inventory and receivables growth. Thirdly, company carried out a direct share issue, providing net proceeds of 1,026 million SEC after transaction cost. And finally, the company executed AGM 2021 authorization to hedge employee stock option social security costs, obtaining 22 million SEK. As end of quarter, TAMURUS has no debt. All in all, TAMURUS closes first quarter 2024 with a strengthened financial position interesting growth opportunities, and is on track to deliver 2024 market guidance. Having said that, I would like to pass the word to Richard. Thank you, everyone, for your attention. Thank you, John.

So, we move over to a commercialization update. I'll start in the cameras markets, and then I will give an update on Brixardi in the U.S. So, in quarter one, invoice sales for Buvedal grew at plus 29% versus previous year at 30% at constant exchange rate. and plus 3% versus Q4, a constant exchange rate. After a strong Q4, we saw softer sales in January and February. However, as expected, in March, we exited the quarter strongly. Importantly, though, underlying in-market demand remained strong and grew at 5% quarter-and-quarter, which more accurately reflects performance in the countries. Sharpened execution on our strategies and plans by the team across countries is driving both access to Buvidal and penetration in clinics and criminal justice settings. And we continue to hear of the positive impact that Buvidal is having on treatment outcomes for patients with opioid dependence. To give some more granularity, we had good progress in the UK, where in market we continue to grow to high single digit and recruit new patients alongside accelerating access in criminal justice settings as NHS funding comes through. But that said, this was tempered slightly by delays in that NHS funding due to the NHS year end that finished in March. In Australia, the recent government changes have reduced co-pay for patients, and we see both numbers in treatment and the numbers on long-acting injectable buprenorphine growing, and we maintain our strong leadership in the long-acting buprenorphine segment with patient share above 80%. Also in the Nordics, France, Spain, and the MENA region all grew well in the quarter, and we remain on track for our market guidance for product sales. We now estimate we have more than 50,000 patients being treated with Buvidal at the which is approaching 30% of the Buprenorphine segment where we have access, though, of course, with an estimated 750,000 patients in treatment in Europe and Australia, there remains a large opportunity for Buvidal in the region. We also continue to expand geographically, and in Q1 achieved reimbursement approval in Ireland, which will allow us to expand Buvidal use in treatment clinics across the country, and we have ongoing processes for both reimbursement and market authorizations in other countries. Now moving to the U.S. with the launch phase of Brixardi. Performance in the quarter in the U.S. saw accelerated penetration as shown by the large increase in our royalty stream from partner Braeburn. Royalty for the quarter was 26 million sec and based on information from Braeburn, after about six months since launch there we already have an estimated 7,000 patients on treatment with Brixardi. This excellent early progress reflects the acceptance of the strong product profile and demand for Brixardi in the country with a high unmet medical need. The compelling messaging around Brixardi is clearly resonating with U.S. healthcare professionals, and Braeburn continue to focus on the launch strategy and execution with a commercial team of more than 100 people. And they have strong payer coverage already on par with other long-acting injectable products in OUD and a channel development that provides quick and reliable access to Brixardi. And based on the strong performance of Brixardi in the U.S., our expectations of reaching peak sales above 1 billion has been reinforced. We also continue to build and share the evidence base to highlight the advantage Buvidal brings for those seeking treatment for opioid dependence and data that supports a differentiated product profile. Firstly, a recent publication on opioid blockade affirms the need to individualize treatment and titrate doses for optimal treatment outcomes and demonstrated blockade across the dose range for Buvidal and Bruxardi. Other publications from Australia show how long-acting buprenorphine is individualized in the country with broad utilization of all treatment doses in real clinical practice. So on that note, I will hand back to Fredrik for an update on the pipeline.

Thank you so much, Richard, and I'll give a late stage development update and focusing here on CAMP 2029. During the quarter, we continue to advance 2029 across target indications, which are acromegaly gastroenteropancreatic neuroendocrine tumors of course as you have heard previously here polycystic liver disease and the product is designed for both enhanced efficacy improved patient convenience and also quality of life as our clinical program have progressed with positive study data outcomes our expectations for camp 2029 across the indications has been reinforced So, moving to a short update on each program in Acromegaly, we have completed treatment of all patients in Acruinova 2, our long-term safety and efficacy study, and we provide updated study results at the end of the second quarter, building on the previously communicated positive interim results. In parallel, the FDA review of Oclase has been progressing, and we recently submitted a corresponding market authorization application for CAMP 2029 to the European Medical Agency. In GetNet, after completing enrollment at the end of last year, we are now collecting data and monitoring progression-free survival events until we reach the target of 194. to read out the primary superiority endpoint. And in PLD, we completed during the quarter enrollment of all 72 patients in the randomized placebo-controlled Positano trial, which primary endpoint is to demonstrate reduced liver volume and improved symptoms in patients with symptomatic polycystic liver disease. So, we continue to meet our objectives and timelines for CAMP 2029 across indications, and have several important milestones ahead of us in the coming year. These include final results from the core phase of ACRInova 2, which we expect to be able to present at the end of June, and FDA approval decision for acromegaly by the PDUFA date of the 21st of October 2024, followed by the planned U.S. launch of Oclase for treatment of acromegaly in the U.S. around the year end. In GapNet, we're expecting to finalize the core phase of the Sorrento trial in the first half of 2025, and thereafter obtain top-line results on the progression-free survival and other key endpoints. This will and should allow an NDA submission to the FDA sometime during the second half of next year and an application in other geographies they would of course follow as closely as possible finally top line results from positano in poly in the pld indication are expected early 2025. So in parallel with the advances of the registration programs, we continue to build our U.S. commercial organization to prepare for the planned workplace launch. The estimated market opportunity for CAM 2029 across indications is significant and estimated in the region of about 1.5 billion U.S. dollars. During the period, we started onboarding key functions in medical affairs, marketing, and commercial. We also signed a lease for our new office space in Princeton, New Jersey. Market research has been ongoing, primarily for the Acromegaly and NET indications, providing insight on patient, prescriber, and payer perspectives, and enabling the team to build out their launch plan. We have also been active with payer engagement and setting up the distribution and patient support model. Medical affairs activities have been accelerated in the quarter and this has been reflected in the number of events that we are participating in. We have cameras and study investigators sharing data from the ACRI-NOVA program and updating on Sorrento and Positano trials at scientific meetings throughout 2024. Key upcoming conferences include the European Congress of Endocrinology in Stockholm the coming week. And then later on in May, we are attending the end of meeting in Boston, which will be starting, I think it is the 30th of May this year. So with that, Short update on the business of cameras. I'm pleased with the performance of our teams and the partners that we are working with, continuing execution, which in the quarter has delivered revenues and profitability in line with guidance, robust in-market growth for Bovidal, and a very strong momentum for Britsady in the US, which we are very pleased with. The MDA was accepted for review by FDA and we are on track for an anticipated approval decision in October. In parallel, we have made significant progress on other pipeline programs, including the ones I mentioned earlier today, and cameras ended the quarter with strength and cash position of 2.3 billion SEC to support future organic growth and also in an organic initiatives. So with that, I thank you for your attention, and I leave it over to Einar here to please start out the Q&A.

Thanks, Erik. If you wish to ask a question, please press pound key five on your telephone keypad. The first question comes from the line of Erik Hultgård from Carnegie. Please go ahead. Your line is open.

Yes, hi there. Thanks for taking my questions. I have A few, if I may. First on Buvidal, the pace of quarterly patient growth slowed to 2K from being stable at 3K the past two years. And I think you mentioned UK funding delay, but I assume it can't explain the full delta. So can you please provide some color here and more specifically if you're starting to see a saturation in some of the early launch markets? And then I have two on the monthly SEMA project. First, have you looked in preclinical models on whether your fluid crystal technology can enable higher exposure of SEMA versus the original product in animals? And I think as a reference, with Octuritide, you've achieved a higher exposure with CAM-2029 compared to Sandostatin-LAR. So I was just wondering if this could be the case as well for SEMA. And then just the short final one, when do you plan to publicly share the preclinical data generated on the monthly SEMA today? Thank you.

Thank you. So I think we'll let Richard start with a question about the softening in January and February.

Yes, I'm happy to say that. Yeah, we did see a slight slowdown in the first two months of the quarter. Partly, as we said, is the UK, the funding delay coming there and some of the changes are happening in Australia. Overall, I think it's just a slight slowdown for that quarter. We're back to growth now. We exited the quarter strongly and we believe that we're going to pick up that growth rate the same as we were. I don't think it's around saturation. As I said, there's a lot of patients needing treatment in Europe um and we still have a long way to go and a lot of opportunity there and i think we're seeing increasing um demand from patients for long-acting treatments as well so we only see that accelerating in the future okay uh is that that moving over to your question about higher exposure i think what we see is that we have quite good flexibility in terms of exposure

and i i can say that i don't think that's a limiting aspect for our technology in in terms of semi-glutine so i mean there are many other considerations of course in this treatment and and and they have to be considered but i think we can say that with with strong confidence that we can provide significant overall exposure during the treatment period um whether or not it from a bioavailability perspective because that's that's the difference we're seeing with in the camp 2029 case i i don't think i can give you the indication that we have a significantly better bioavailability because here we're comparing a non-form essentially non-formulated system which theoretically should have 100 by availability compared to a formulated system is that

Yeah, so you mean in terms of bioavailability, it's fair to assume that you will have some type of trade-off when you go to formulate the monthly version. So it's fair to assume that you don't.

No, that's, I don't think you, that assumption I did not kind of confirm. On the contrary, I mean, with cancer at 29, we essentially have 100% bioavailability, so we don't have, I would say that having improved bioavailability is something I cannot confirm. I think my message is we can reach, you know, therapeutic levels across the current dose range.

All right. Thank you.

The next question from Brian from Jefferies. Please go ahead. Your line is open.

Hey. Thank you, guys. First question is around brixadi. Strong launch. I couldn't see anything in the release, but just wanted to check if you saw any impact from the change healthcare cyber attack on Brixardi invoicing new patient starts as Indivior had reported that to be the case to them or Sublocade. Second, just again on that GLP-1 phase one study, I guess, what is the limit to the molecular size with your fluid crystal test? Could you potentially go greater than 40 And then just on the study, it is partnered with Nova Nordisk. And if so, what are the economics? And I've got a third question, but I'll stop there now.

Okay. So, I mean, if we start out with your first question here, I don't think we have seen, and we haven't heard any reports that we had any impact of a cyber attack. on the other hand uh yeah so so this this has not been anything that we have been communicated by our partner in the us and now we haven't asked specifically uh regarding this topic but but we haven't heard any information about that so when it came to uh yeah the second topic

Can you? The second topic is which is the limit of the molecule size?

Oh, yeah. So, yeah, sorry. I mean, I think we have successfully formulated and performed preclinical studies for peptide or small protein compounds, at least up to 20 kilodaltons. But, you know, it's always difficult to generalize. So that's, of course, much more than 30 amino acids. So that is not the limit. Always when you're talking about these things, you have to consider many different aspects, but I would say that we are not limited to 30 amino acids, for instance. And then the third question, if we see this partner, we know. Yes, I mean, we have not announced anything about partnering or relationships with other parties in relationship to the semaglutide project.

Got it. And then just thirdly, on the GetNet study phase three that we got, first half of 25, can you just help us understand how the tougher patient population in the Sorrento study could mean that the comparator arms of Xanastatin and Somaxa could potentially underperform versus what we've seen historically from their phase three studies? Thank you.

Yeah, we are not assuming the performance from this for the comparator arm. Of course, it depends on which study you are referring to. But definitely, if you're referring to the clarinet study, which ships and perform. I mean, there you had a progression risk free survival, which was very long. I would say that in that study was essentially a large majority of patients were grade one patients. uh with low uh proliferation rates when it comes to tumor proliferation so below two uh we have a much broader and in a sense more representative population in sorrento uh with a majority actually of the grade two patients so from that aspect they have more advanced neuroendocrine tumor states and the we also have higher KI67 proliferation index values. So I think that's the basis that we have had in our assumptions, and I think the population we assumed when we started the study is very much reflecting the population that we now have in the study after recruiting all patients. Anything else, Brian? Great. That's fantastic.

The next question is from Mattias Heggblom from Handelsbanken. Please go ahead. Your line is open.

Yeah, thanks so much for taking my question, Mattias Heggblom from Handelsbanken. I have two questions, please. So on my calculation, sales of Huvidal in your largest market, Australia, declined in local currencies by 14% sequentially during the quarter. You refer to inventory fluctuations, but can you share what in-market sales growth you saw in Australia, or was there any additional dynamic in the quarter that explained the performance in Australia? And then secondly, I guess on the monthly SEMA, can you say anything why now? Because GLP-1 and analogs have been listed for molecular classes where fluid crystal is applicable in presentation, I think, already back since 2018. So have you achieved a technology breakthrough that you couldn't accomplish before, or is there time left of IP? that now has accelerated this program.

So, thanks a lot, Matias. So, regarding your question about booby-dallop reported rate is correct. If we look at the in-market performance, excluding the SX impact, and then the seasonality of the stocks just remember that australia is going through a change of the supply model at the moment the in-market trend that we see in the australian market is in the range of eight percent yeah and the second question is a technology breakthrough and that's plus yeah yeah it's just plus positive yeah so yeah when it comes to to the breakthrough in this case first of all i should say that

We have been working with this program for some time. I cannot go into details about that. We have made some significant optimization efforts and, of course, done quite a number of studies. So when we are speaking about it this time, it was more because we have taken the decision to move ahead towards the clinic. But we have optimized the formulation work, and we have got the preclinical data that we felt was required for us to take the next step in various different preclinical settings and models.

That's clear. And then I have one follow-up.

Yeah, regarding the intellectual property question. I mean, semis, as we understand it, depends on geography, but it's an interesting time range, 2029. I think the original patent expires, but they have patent extension term that goes to 3132. We'll see how that finally will pan out, but it's a good time and phase to look into this development.

Thank you. And then, yeah, that's clear. That's clear. I have one follow up or, or, or rather not related to this, but, but coming back to Brick Saudi and the impressive ramp and royalty generation, the first quarter. So is there any risk that there is some kind of stocking in Q Q one that drove this three times sequential increase? I guess another way of asking is the royalty triggered by sales into the channel. including potential stocking, or is it driven by in-market sales?

The royalty is not driven by what is put into the channel. It's what the channel is distributing to their customers. This doesn't mean that all the merchandise can be distributed to patients, because there can be small deposits in the channel. So, I'm trying to reply to your question, Mathias.

But if we go into this question also, I don't think there is any tendency that this should be represented by a large stock up. On the contrary, the patient numbers that have been provided are patient numbers from Rayburn, and they are reflective of the fact that the stock is being used in the market.

That's very clear. That's very clear. Thanks so much.

Okay. Thank you.

The next question is from Maria Vara from Brian Garnier and Company. Please go ahead. The line is open.

Hello. Good afternoon. Thank you for taking my question. I just wanted to have a bit of an update on the buildup of the U.S. organization and sales force. How is this moving along in regards to the launch of Come 2029 in the U.S.? Can you maybe remind us the sales reps that you will be targeting? Thank you.

So, yeah, we are going ahead, and it's going very well right now. Our focus is very much on the medical affairs side. And, of course, the whole system backup, so we have everything from compliance to other functions are now put in place in the U.S. In terms of the strategy going forward, I think I'll leave over to John. Maybe you can just give a summary of where we are with the SAFE strategy in the US.

Yes. So where we are in terms of the SAFE strategy and sales team is we are going to build it up on a phase side. We are bringing in, and we already have. I see having disclosed our US president, but we also have the head. of marketing and sales, our VP in the market, and right now we are working in parallel to start developing how the product will be distributed into the market, so supply chain model, patient hub model, and which are the partners that they are going to support into this area. In parallel, we are working quite intensively with payers to try to ensure that the product can be accessed as soon as possible in the in the market and that's where is our focus for i would say q2 and probably q3 then after pedophilia all the cell phones will be on board and we are trying to work ahead of the pedophilia to identify the relevant talent that can be joining our company and i think adding to that of course you also asked about uh you know the the uh

um the targeting of the product in the market and we have been working very intensively with that both own studies and we have had a number of regional studies performed identifying the prescribers and and also the centers of of largest interest so so that is an activity that has been prioritized and we are continuing Any further questions from you, Marianne?

Yeah, great. That's super helpful. Thank you. That's all from my side.

The next question is from Christopher Ude from SCB.

Please go ahead. Hi there. Thanks for taking my questions. So you've previously enumerated why 2024 will be back-end loaded, and yet in Q1, you've delivered in line with the midpoint of top-line guidance. Why have you not raised the guide? Should we interpret this to mean that you're less confident about the favorable factors impacting market access and reimbursement in the EU5 actually transpiring than you maybe were previously? That's my first question.

Christopher, I think, I mean, what we're saying and we're communicating is that we are basically tracking along the middle of our guidance that's the response that we have provided now and if you're looking i mean obviously we will have different models but i think we have not found a reason to change our guidance at this point And we are expecting to follow this track going forward. I mean, John, do you have anything that you would like to add there?

No. So far, our major investment areas are the U.S. It's public information. We disclose we intend to increase our investment level by 300 million SEC, mostly related to the U.S. And we are progressing online with our activities. So the investment will increase, especially in the second half of the year. And right now, we are aligned with the guidance we have provided. In the top line, if I remember okay, our company revenue has grown 37%, which is exactly the midpoint of providing guidance for the full year, 33% to 42%. And it is true that our profit before taxes has been strong versus what the market was expecting, 97 million SEG. But still, we have nine months to go, and we expect to reach the investment of 1.3, slightly above 1.3 billion, as we provided in our guidance. So right now, we, in the first quarter, three months have started, and we don't see solid reasons to change our guidance.

Okay, great. And then I guess my second question would be, So one of your competitors recently talked about partnerships with pharmacy grocery chains to be able to enable patients to administer the product in more convenient locations, so I guess closer to patients' homes. Is this something that you guys are working on? Do you see it as a potential key driver, or is it just one more piece of the puzzle? And then I guess while I'm still on the subject of the OUD, in terms of competition, in some of your early launch markets, you now have, yeah, more than you had before perhaps. To what extent are you feeling or noticing this impact?

I didn't understand the last question, the finish of that question, but can you repeat that?

Yeah, sure. So to what extent the impact was? of competition, I guess you have other long-acting. Okay.

Are you noticing it? Okay, that's a very good question. So, I mean, we can start with that. I think that in most of our markets, or all of our markets, we haven't seen the competitive landscape change very significantly. I would say, in any geographic territory yet. So, of course, the US is in a new situation, but otherwise, in the markets where we are very strong, like Finland, extremely strong, we continue to see growth, which we, of course, are very happy with. And we haven't seen a big penetration of any competitive product yet. When it comes to alternate pathways and distribution models in the US, I would say that we have, and I think that we have mentioned this in earlier presentations, that we have developed a kind of pharmacy chain injection model, which is being used, especially in the Australian territory, because there were a kind of a stock up or there was a difficulty capacity limitation you could say in specialty clinics and this model is being applied elsewhere and i think there's very important rooms here and this is also an important initiative for patient in our different markets and similarly in the us i cannot about this topic here, but I understand that it's the model that INDIVIER is developing, for instance. And of course, it's reasonable to expect that other parties are using similar approaches. But it is a very important thing because, I mean, this, we should optimize the pathways for these patients and make treatment as accessible as possible. both regionally and in the large cities. And I think there's a large possibility in just improving these systems going forward. So I can only confirm the importance of this.

Okay, great. Thanks. And then I guess my last question would be on the pipeline. What can you tell us about the additional GLP-1 analogs you're testing that you mentioned, including whether any is proprietary? And for semaglutide, would you seriously consider taking this to market without a partnership with NOBO? Thanks. That's all from me.

Okay. When it comes to the first question, I mean, we will communicate, you know, as we go along, specifics. at this point i think there is this is not our intention but we have some interesting programs going forward they are still a little bit earlier in terms of development so therefore we are not choosing to communicate um yeah on on that note when it came what was the second question oh yes i mean uh We have only decided to develop the product up to and beyond first clinical trial. Whether or not we will change our focus and do phase two or other trials, this would be a topic for the future. But obviously, we are not expecting to be marketing products in the large indications here. But this is something that we will think about and communicate going forward. But our primary intent is not to bring this to commercialization. Thanks very much. I cannot comment on the normal question.

The next question is from Jon Håkon Findräng from Tind Asset Management. Please go ahead.

Hi there, and thank you for taking my question. So first of all, congrats on the quarter and particularly the development in the US. And I have two questions. So the first one is on the GLP-1 study related to Novo Nordisk. And I guess the idea here is to open up for monthly shots. But is there also other benefits to this? And can you say something about the potential? And secondly, I understand that the development in Bovidal may be affected by stocking. Is this again related to the development in your working capital for the quarter?

Okay, yeah, well, starting out with the first question about GFP1s, of course, there are multiple considerations there. I mean, everything from the titration process up to therapeutic levels or to so dose increases to convenience of weekly or monthly treatments and this is also dependent on the patient group of course longer duration products have specific and maybe the highest interest in in in groups where compliance is challenging but uh i mean as a general rule the larger the the uh time frame between administrations the better for the patient as long as you have the the correct pk profile so so i think the benefits can be everything from compliance titration up to the efficacy and exposure range that that you are able to cover with the product so and we are of course looking into all of these aspects i think the second question i'll just leave over to john and are you is that sufficient on the gfb1 john uh all good and regarding working capital the answer is yes partially the increase in our inventories is due to that

But also we have made a conscious decision to try to increase the store level single materials aspect. So this is a conscious company decision. So it's a combination of both.

Thank you very much. That's all for me.

There are no more questions at this time, so I'll hand the word back to you Fredrik.

Okay, thank you so much. I think all I want to say is thank you for joining this call and I'm looking forward to uh giving you the next update in june or in july the 17th so until then have a great day and please enjoy the holidays if you have them coming up here